Zacks: Analysts Expect Microbot Medical Inc. (NASDAQ:MBOT) to Post -$0.42 EPS

Equities analysts predict that Microbot Medical Inc. (NASDAQ:MBOTGet Rating) will report earnings per share of ($0.42) for the current quarter, according to Zacks. Zero analysts have made estimates for Microbot Medical’s earnings. Microbot Medical posted earnings of ($0.34) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 23.5%. The business is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Microbot Medical will report full-year earnings of ($1.85) per share for the current financial year. For the next fiscal year, analysts anticipate that the company will post earnings of ($1.53) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Microbot Medical.

Separately, Zacks Investment Research raised Microbot Medical from a “sell” rating to a “hold” rating in a report on Thursday.

A number of institutional investors have recently bought and sold shares of MBOT. BlackRock Inc. grew its stake in Microbot Medical by 11.7% during the third quarter. BlackRock Inc. now owns 155,013 shares of the biotechnology company’s stock worth $1,090,000 after purchasing an additional 16,205 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Microbot Medical by 78.1% in the third quarter. Dimensional Fund Advisors LP now owns 95,064 shares of the biotechnology company’s stock valued at $668,000 after buying an additional 41,686 shares during the period. Morgan Stanley raised its stake in shares of Microbot Medical by 454.7% in the third quarter. Morgan Stanley now owns 19,438 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 15,934 shares during the period. Renaissance Technologies LLC grew its position in shares of Microbot Medical by 52.5% in the first quarter. Renaissance Technologies LLC now owns 15,695 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 5,400 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Microbot Medical in the fourth quarter valued at $95,000. Hedge funds and other institutional investors own 11.45% of the company’s stock.

Shares of Microbot Medical stock opened at $5.95 on Thursday. The company’s fifty day simple moving average is $5.70 and its 200-day simple moving average is $5.76. Microbot Medical has a 1 year low of $4.31 and a 1 year high of $9.60.

Microbot Medical Company Profile (Get Rating)

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio.

See Also

Get a free copy of the Zacks research report on Microbot Medical (MBOT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with's FREE daily email newsletter.